Search Results

You are looking at 51 - 60 of 251 items for :

  • malignant pheochromocytoma x
  • Refine by Access: All content x
Clear All
Free access

V Häyry, K Salmenkivi, J Arola, P Heikkilä, C Haglund, and H Sariola

Peters B Mawrin C Hoang-Vu C Roessner A Lehnert H 2003 Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma . Journal of Clinical Endocrinology and Metabolism 88 4280 – 4286 . Boulay

Free access

D Cecchin, F Lumachi, M C Marzola, G Opocher, C Scaroni, P Zucchetta, F Mantero, and F Bui

. Quarterly Journal of Nuclear Medicine 39 3 –8. Shapiro B , Gross MD & Shulkin B 2001 Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends in Endocrinology and Metabolism 12 469 –475

Free access

Ioana N Milos, Karin Frank-Raue, Nelson Wohllk, Ana Luiza Maia, Eduardo Pusiol, Attila Patocs, Mercedes Robledo, Josefina Biarnes, Marta Barontini, Thera P Links, Jan Willem de Groot, Sarka Dvorakova, Mariola Peczkowska, Lisa A Rybicki, Maren Sullivan, Friedhelm Raue, Ioana Zosin, Charis Eng, and Hartmut P H Neumann

and pheochromocytoma were diagnosed simultaneously. Malignant pheochromocytoma was not observed in any of the 41 patients. HPT Parathyroid data were available for 64 carriers. HPT was present in six (9%) patients. Mean age at diagnosis was 39 years

Free access

Alexandra Chrisoulidou, Gregory Kaltsas, Ioannis Ilias, and Ashley B Grossman

:upregulation in malignant phaeochromocytoma and downregulation in adrenocortical carcinoma. Endocrine Pathology 13 99 –110. Koch CA , Vortmeyer AO, Huang SC, Alesci S, Zhuang Z & Pacak K 2001 Genetic aspects of pheochromocytoma

Open access

Nimrod B Kiss, Andreas Muth, Adam Andreasson, C Christofer Juhlin, Janos Geli, Martin Bäckdahl, Anders Höög, Bo Wängberg, Ola Nilsson, Håkan Ahlman, and Catharina Larsson

extended tumor panel of pheochromocytomas and paragangliomas. Notably and as our previous findings indicated a presence of CIMP in strong association with malignant paragangliomas with SDHB mutation ( Geli et al . 2008 , Kiss et al . 2008 ), the

Free access

R Nawar and D Aron

as differentiates between benign and malignant adrenal tumors. MIBG has the advantage over CT or MRI in that it provides a whole-body image with the administration of one tracer dose. Pheochromocytomas can occur bilaterally and may not be confined to

Free access

Camilo Jimenez, Sasan Fazeli, and Alejandro Román-Gonzalez

World Health Organization (WHO), however, recognizes that all pheochromocytomas and paragangliomas have the potential to spread distantly and recommends that the term 'malignant' be avoided in this setting, for example, 'metastatic tumor' is preferred to

Free access

Maya B Lodish, Karen T Adams, Thanh T Huynh, Tamara Prodanov, Alex Ling, Clara Chen, Suzanne Shusterman, Camilo Jimenez, Maria Merino, Marybeth Hughes, Kendall W Cradic, Dragana Milosevic, Ravinder J Singh, Constantine A Stratakis, and Karel Pacak

patients with malignant pheochromocytomas or paragangliomas . Journal of Clinical Endocrinology and Metabolism 92 3822 – 3828 . Astuti D Latif F Dallol A Dahia PL Douglas F George E Skoldberg F Husebye ES Eng C Maher ER 2001

Free access

Hans K Ghayee, Bas Havekes, Eleonora P M Corssmit, Graeme Eisenhofer, Stephen R Hammes, Zahid Ahmad, Alexander Tessnow, Ivica Lazúrová, Karen T Adams, Antonio T Fojo, Karel Pacak, and Richard J Auchus

/or pheochromocytomas. SDHD-associated malignant disease is considered rare ( Benn et al . 2006 , Havekes et al . 2007 , Timmers et al . 2007 ). PGLs caused by germ line SDHB mutations show hypersecretion of both norepinephrine and dopamine in 46% and

Open access

Camilo Jimenez, Bennett B Chin, Richard B Noto, Joseph S Dillon, Lilja Solnes, Nancy Stambler, Vincent A DiPippo, and Daniel A Pryma

Babich JW 2009 Radiation dosimetry, pharmacokinetics, and safety of ultratrace iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid . Cancer Biotherapy and Radiopharmaceuticals 24 469 – 475 . ( https